Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
Takenaka K, Eto T, Nagafuji K, Kamezaki K, Matsuo Y, Yoshimoto G, Harada N, Yoshida M, Henzan H, Takase K, Miyamoto T, Akashi K, Harada M, Teshima T; for Fukuoka Blood and Marrow Transplant Group (FBMTG).
Takenaka K, et al. Among authors: harada m, harada n.
Int J Hematol. 2009 Mar;89(2):231-237. doi: 10.1007/s12185-008-0249-2. Epub 2009 Jan 17.
Int J Hematol. 2009.
PMID: 19148587
Clinical Trial.